⚠️ Differentiation Syndrome is a life-threatening complication of therapy with differentiating agents such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in the treatment of Acute Promyelocytic Leukaemia (APL). Prompt recognition and steroid treatment are essential to reduce mortality.

📘 About

Previously known as “Retinoic Acid Syndrome”.
Occurs in patients receiving ATRA or ATO during induction therapy for APL.
Represents an inflammatory capillary leak syndrome resulting from rapid differentiation of malignant promyelocytes.
Mortality can reach 10–20% if not promptly treated, but is reversible with corticosteroids if recognised early.

🧬 Aetiology / Pathophysiology

ATRA and ATO induce differentiation of leukaemic blasts into mature granulocytes.
Differentiating cells secrete cytokines and vascular factors (e.g. IL-1β, IL-6, TNF-α, VEGF) causing endothelial activation, capillary leak, and tissue infiltration.
This leads to fever, pulmonary oedema (ARDS), renal impairment, and hypotension.
Histologically characterised by interstitial infiltration of maturing myeloid cells with oedema.

⚠️ Clinical Features

Typically develops 7–12 days after initiation of ATRA/ATO.
Early symptoms: fever, weight gain, bone pain, malaise.
Progresses to:
- Respiratory distress / ARDS
- Oedema and serosal effusions (pleural, pericardial)
- Hypotension and acute kidney injury
Severe cases can lead to multiorgan failure if untreated.

🧪 Investigations

📉 Coagulopathy: transient abnormalities resembling DIC.
📈 LFTs: raised transaminases and triglycerides.
🩻 Chest X-ray: interstitial or alveolar infiltrates, pleural effusions.
🫀 Echocardiography: may reveal pericardial effusion.
🧫 Bloods: elevated inflammatory markers and WCC (leukocytosis).

🚨 Differential Diagnosis

Sepsis or pneumonia (may mimic the same respiratory findings).
Fluid overload or cardiac failure post-chemotherapy.
Disseminated intravascular coagulation (DIC) from APL itself.

🩺 Management

🏥 Emergency recognition: suspected cases should be treated immediately — do not wait for confirmation.
💉 Corticosteroids:
- Dexamethasone 10 mg IV every 12 hours until symptoms resolve.
- Continue for ≥3 days or until stable; taper as appropriate.
💊 Supportive therapy: oxygen, diuretics, fluid balance monitoring, and treatment of renal impairment.
🧬 ATRA/ATO adjustment: withhold or reduce dose in severe cases, restart cautiously once stabilised.
🛡️ Prevention: prophylactic dexamethasone 2.5–5 mg BD during induction in high-risk patients (e.g. WCC >10×10⁹/L).

💡 Key Learning Points

Occurs only with differentiating therapies (ATRA, ATO).
Results from cytokine-mediated capillary leak and organ infiltration.
Dexamethasone is life-saving — treat on suspicion.
Do not confuse with sepsis — patients may be afebrile or non-toxic despite infiltrates.
Monitor WCC, weight, and respiratory status closely during induction.

📚 References

Frankel SR et al. Differentiation syndrome: pathophysiology, prevention, and treatment. Leukemia 2011;25(11):1763–1771.
Lo-Coco F, Avvisati G et al. Management of differentiation syndrome in APL: an update. Blood Rev. 2014;28(3):117–122.
BNF: Tretinoin (All-trans-retinoic acid)

💡 Teaching tip: Differentiation syndrome should be treated as a medical emergency in all APL patients on ATRA/ATO who develop fever, hypoxia, or oedema. Immediate dexamethasone can be life-saving — never delay treatment while awaiting confirmation.

The content on this website is provided for educational and informational purposes only to support exam preparation (e.g., MLA, MRCP, USMLE) and learning. This is NOT medical advice, diagnosis, treatment, or professional guidance. It does not replace consultation with a qualified healthcare professional, official guidelines (e.g., NICE, GMC, BNF), or supervised clinical practice. Always verify information with current, authoritative sources. Makindo and its contributors accept no liability for any reliance on this content, including errors, omissions, or any resulting harm, loss, or consequences. By using this site, you agree to these terms.

Differentiation syndrome